Agilon Health, Inc. (NYSE:AGL) Given Average Recommendation of “Hold” by Brokerages

Shares of Agilon Health, Inc. (NYSE:AGL) have been assigned a consensus recommendation of “Hold” from the seventeen ratings firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $2.7083.

A number of equities analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Barclays lowered their price target on shares of Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a report on Thursday, November 6th. Wells Fargo & Company reduced their price objective on Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. BTIG Research restated a “neutral” rating on shares of Agilon Health in a research report on Friday, December 12th. Finally, Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd.

Agilon Health News Roundup

Here are the key news stories impacting Agilon Health this week:

• Neutral Sentiment: Market context: AGL has seen increased trading activity and a short‑term price uptick despite the legal filings; that bounce may reflect low float, speculative trading or short covering rather than a change in fundamentals.
• Negative Sentiment: Rosen Law Firm reminds purchasers of AGL of the March 2, 2026 lead‑plaintiff deadline and is soliciting investors who suffered losses during the alleged class period — this is part of a coordinated push to identify lead plaintiffs and pursue a securities suit. Rosen Law Firm Notice
• Negative Sentiment: Multiple national firms (Pomerantz, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Levi & Korsinsky, The Gross Law Firm, Bernstein Liebhard, Kirby McInerney, Schall, etc.) have filed or issued investor notices seeking plaintiffs and claiming investor harm — the accumulation of these actions raises potential litigation, defense costs, and settlement risk for AGL. Representative PR Newswire Notice
• Negative Sentiment: Practical impact for investors: if a lead plaintiff is appointed and the litigation proceeds, AGL could face material legal liabilities, increased governance scrutiny, and downward pressure on the share price; monitor SEC filings, company disclosures, and any governmental inquiries closely. Bronstein Notice

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AGL. Goldman Sachs Group Inc. boosted its position in shares of Agilon Health by 196.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock valued at $13,812,000 after buying an additional 13,283,930 shares during the period. AQR Capital Management LLC raised its holdings in shares of Agilon Health by 1,346.6% in the fourth quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company’s stock worth $7,033,000 after buying an additional 9,505,837 shares during the period. CenterBook Partners LP lifted its stake in shares of Agilon Health by 492.4% during the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock worth $11,771,000 after acquiring an additional 9,499,012 shares during the last quarter. North Peak Capital Management LLC lifted its stake in shares of Agilon Health by 10.8% during the 4th quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock worth $26,267,000 after acquiring an additional 3,715,460 shares during the last quarter. Finally, Voleon Capital Management LP boosted its holdings in Agilon Health by 5,519.2% during the 3rd quarter. Voleon Capital Management LP now owns 2,741,039 shares of the company’s stock valued at $2,823,000 after acquiring an additional 2,692,259 shares during the period.

Agilon Health Stock Performance

AGL stock opened at $0.44 on Monday. The firm has a fifty day moving average price of $0.73 and a 200 day moving average price of $0.87. Agilon Health has a fifty-two week low of $0.34 and a fifty-two week high of $6.08. The firm has a market cap of $181.71 million, a PE ratio of -0.58 and a beta of 0.06.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.